Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients

Cancer Immunology, Immunotherapy

Volumn 63, Issue 7, 2014, Pages 737-747

  Herrera, Zaima Mazorra ^a   Ramos, Tania Crombet ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Cancer vaccines; CIMT 2013; Combination; Epidermal growth factor; NGcGM3 ganglioside; NSCLC

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; ERLOTINIB; IMMUNOMODULATING AGENT; IPILIMUMAB; MONTANIDE ISA 51; PLACEBO; RACOTUMOMAB; RECOMBINANT EPIDERMAL GROWTH FACTOR; UROKINASE;

ADVANCED CANCER; ANTIBODY RESPONSE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL MEMBRANE; CELL PROLIFERATION; CLINICAL STUDY; EHRLICH ASCITES TUMOR; FUNCTIONAL STATUS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; NEISSERIA MENINGITIDIS; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; RECURRENCE FREE SURVIVAL; REVIEW; T LYMPHOCYTE; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84903817256     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1552-9     Document Type: Review

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Kostyleva OI, Gershtein ES, Dykhno A, Polotskii BE, Vasil'ev AV, Kushlinskii NE (1999) Clinical and prognostic importance of the expression of epidermal growth factor receptors in non-small-cell lung carcinoma. Biull Eksp Biol Med 127:446-449
3. Blanco R, Rengifo CE, Cedeño M, Frometa M, Rengifo E, Carr A (2012) Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a positive prognostic factor in non-small-cell lung cancer. Pathol Res Int 2012:235418
4. Hayashi N, Chiba H, Kuronuma K et al (2013) Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci 104:43-47
5. de Leon J, Fernández A, Mesa C, Clavel M, Fernández LE (2006) Role of tumour-associated N-glycolyated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 55:443-450
6. Jerne NK (1974) Towards a network theory of the immune system. Ann Immunol (Paris) 125C:373-389
7. Chapman PB (2003) Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Curr Opin Investig Drugs 4:710-715
8. Chong G, Bhatnagar A, Cunningham D et al (2006) Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Ann Oncol 17:437-442 (Pubitemid 43329580)
9. Reinartz S, Kohler S, Schlebusch H et al (2004) Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 10:1580-1587 (Pubitemid 38435546)
10. Sabbatini P, Harter P, Scambia G et al (2013) Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study. J Clin Oncol 31:1554-1561
11. Giaccone G, Debruyne C, Felip E et al (2005) Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 23:6854-6864
12. Irie A, Suzuki A (1998) CMP-N-Acetylneuraminic acid hydroxylase is exclusively inactive in humans. Biochem Biophys Res Commun 248:330-333 (Pubitemid 28386421)
13. Marquina G, Waki H, Fernández LE, Kon K, Carr A, Valiente O, Pérez R, Ando S (1996) Gangliosides expressed in human breast cancer. Cancer Res 56:5165-5171 (Pubitemid 26383031)
14. van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, Giaccone G (2009) Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer 9:180
15. Díaz Y, González A, López A, Pérez R, Vázquez AM, Montero E (2009) Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol Immunother 58:1117-1128
16. Alfonso M, Díaz A, Hernández AM, Pérez A, Rodriguez E, Bitton R, Pérez R, Vázquez AM (2002) An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 168:2523-2529 (Pubitemid 34171859)
17. Díaz A, Alfonso M, Alonso R, Saurez G, Troche M, Catala M, Diaz RM, Pérez R, Vázquez AM (2003) Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 107:80-89
18. Guthmann MD, Castro MA, Cinat G, Venier C, Koliren L, Bitton RJ, Vázquez AM, Fainboim L (2006) Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother 29:215-223
19. Soriano JL, Batista N, Santiesteban E et al (2011) Metronomic cyclophosphamide and methotrexate chemotherapy combined with 1E10 anti-idiotype vaccine in metastatic breast cancer. Int J Breast Cancer 2011:710292
20. Yin J, Hashimoto A, Izawa M et al (2006) Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res 66:2937-2945
21. Alfonso S, Díaz RM, de la Torre A et al (2007) 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol Ther 6:1847-1852 (Pubitemid 351590395)
22. Hernández AM, Toledo D, Martínez D et al (2008) Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 181:6625-6634
23. Pavelic K, Banjac Z, Pavelic J, Spaventi S (1993) Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 13:1133-1137 (Pubitemid 23247476)
24. Masago K, Fujita S, Hatachi Y, Fukuhara A, Sakuma K, Ichikawa M, Kim YH, Mio T, Mishima M (2008) Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer. Cancer Sci 99:2295-2301
25. Vollebergh MA, Kappers I, Klomp HM, Buning-Kager JC, Korse CM, Hauptmann M, de Visser KE, van den Heuvel MM, Linn SC (2010) Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 5:1939-1948
26. Schmitz KR, Ferguson KM (2009) Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res 315:659-670
27. Quatrale AE, Porcelli L, Silvestris N, Colucci G, Angelo A, Azzariti A (2011) EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front Biosci 16:1962-1972
28. Pirker R, Pereira JR, Szczesna A et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373:1525-1531
29. Perol M, Chouaid C, Perol D et al (2012) Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 30:3516-3524
30. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246
31. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132 (Pubitemid 41058344)
32. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
33. Cappuzzo F, Ciuleanu T, Stelmakh L et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529
34. González SB, Suárez E, Beausoleil I, Perez O, Lastre M et al (1996) Induction of immune recognition of self-epidermal growth factor (EGF): effect on EGF biodistribution and tumor growth. Vac Res 5:233-244 (Pubitemid 27089202)
35. Rodriguez PC, González I, González A, Avellanet J, Lopez A, Pérez R, Lage A, Montero E (2008) Priming and boosting determinants on the antibody response to an epidermal growth factor-based cancer vaccine. Vaccine 26:4647-4654
36. González G, Lage A (2007) Cancer vaccines for hormone/growth factor immune deprivation: a feasible approach for cancer treatment. Curr Cancer Drug Targets 7:229-241 (Pubitemid 46699074)
37. Hirsch FR, Herbst RS, Olsen C et al (2008) Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 26:3351-3357
38. Rodriguez PC, Rodriguez G, González G, Lage A (2010) Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev 12:17-23
39. Neninger Vinageras E, de la Torre A, Osorio Rodriguez M et al (2008) Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26:1452-1458
40. García B, Neninger E, de la Torre A et al (2008) Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 14:840-846 (Pubitemid 351231168)
41. Stein WD, Gulley JL, Schlom J et al (2011) Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 17:907-917
42. van Elsas A, Hurwitz A, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-366 (Pubitemid 29374833)
43. Peggs KS, Quezada SA, Korman AJ, Allison JP (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18:206-213 (Pubitemid 43327304)
44. O'Day SJ, Hamid O, Urba WJ (2007) Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110:2614-2627 (Pubitemid 350250330)
45. Chou H, Hayakawa T, Diaz S et al (2002) Inactivation of CMP-N-acetylneuraminic acid hydroxylase occurred prior to brain expansion during human evolution. Proc Natl Acad Sci USA 99:11736-11741 (Pubitemid 34994468)
46. Jo M, Thomas KS, O'Donnell DM, Gonias SL (2003) Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J Biol Chem 278:1642-1646 (Pubitemid 36801395)
47. Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3:932-943 (Pubitemid 35477371)
48. Wang XQ, Sun P, Go L, Koti V, Fliman M, Paller AS (2006) Ganglioside GM3 promotes carcinoma cell proliferation via urokinase plasminogen activator-induced extracellular signal-regulated kinase-independent p70S6 kinase signaling. J Invest Dermatol 126:2687-2696 (Pubitemid 44764053)
49. de Leon J, Fernández A, Clavell M, Labrada M, Bebelagua Y, Mesa C, Fernández LE (2008) Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4 + CD25- effector and naturally occurring CD4 + CD25 + regulatory T cells function. Int Immunol 20:591-600 (Pubitemid 351426051)
50. Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, Jaffee EM, Armstrong TD (2012) Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS ONE 7:e31962
51. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H (2005) Inhibition of CD4(+)25 + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862-2868 (Pubitemid 40446280)
52. Brode S, Cooke A (2008) Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 28:109-126 (Pubitemid 351507425)